Adalimumab, a fully humanized monoclonal antibody specific to TNF-α, is primarily utilized in the treatment of moderate to severe RA, psoriatic arthritis, AS, and Crohn’s disease. This evidence concerns the gene TNF and rheumatoid arthritis.